109 related articles for article (PubMed ID: 20197637)
1. Paradoxical effect of 2,3-dimercapto-1-propanesulfonic acid (DMPS) on enhancing antitumor activity of cisplatin in ascites sarcoma 180 cells.
Sato T; Okubo M; Sawaki K; Maehashi H; Kawaguchi M
J Pharmacol Sci; 2010; 112(3):361-8. PubMed ID: 20197637
[TBL] [Abstract][Full Text] [Related]
2. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
3. Antidotal effects of 2,3-dimercaptopropane-1-sulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the organotoxicity of dibutyltin dichloride (DBTC) in rats.
Merkord J; Weber H; Kröning G; Hennighausen G
Hum Exp Toxicol; 2000 Feb; 19(2):132-7. PubMed ID: 10773844
[TBL] [Abstract][Full Text] [Related]
4. Anti-lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid.
Aposhian HV; Mershon MM; Brinkley FB; Hsu CA; Hackley BE
Life Sci; 1982 Nov; 31(19):2149-56. PubMed ID: 6294430
[TBL] [Abstract][Full Text] [Related]
5. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
6. DMSA, DMPS, and DMPA--as arsenic antidotes.
Aposhian HV; Carter DE; Hoover TD; Hsu CA; Maiorino RM; Stine E
Fundam Appl Toxicol; 1984 Apr; 4(2 Pt 2):S58-70. PubMed ID: 6327446
[TBL] [Abstract][Full Text] [Related]
7. 2,3-Dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid increase mercury- and cadmium-induced inhibition of delta-aminolevulinate dehydratase.
Nogueira CW; Soares FA; Nascimento PC; Muller D; Rocha JB
Toxicology; 2003 Mar; 184(2-3):85-95. PubMed ID: 12499112
[TBL] [Abstract][Full Text] [Related]
8. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.
Shirasaka T; Shimamoto Y; Ohshimo H; Saito H; Fukushima M
Cancer Chemother Pharmacol; 1993; 32(3):167-72. PubMed ID: 8500219
[TBL] [Abstract][Full Text] [Related]
9. Influence of 2,3-dimercaptopropane-1-sulfonate (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the renal disposition of mercury in normal and uninephrectomized rats exposed to inorganic mercury.
Zalups RK
J Pharmacol Exp Ther; 1993 Nov; 267(2):791-800. PubMed ID: 8246154
[TBL] [Abstract][Full Text] [Related]
10. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo.
Araki H; Fukushima M; Kamiyama Y; Shirasaka T
Cancer Lett; 2000 Nov; 160(2):185-91. PubMed ID: 11053648
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent interaction between vinblastine and cisplatin in Ehrlich ascites tumors in mice.
Cemazar M; Auersperg M; Scancar J; Kirbis IS; Pogacnik A; Sersa G
J Pharmacol Exp Ther; 2002 Jul; 302(1):337-43. PubMed ID: 12065735
[TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
Johnson CS; Chang MJ; Yu WD; Modzelewski RA; Grandis JR; Vlock DR; Furmanski P
Cancer Chemother Pharmacol; 1993; 32(5):339-46. PubMed ID: 8339383
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.
Tamura T; Fujita F; Tanimoto M; Koike M; Suzuki A; Fujita M; Horikiri Y; Sakamoto Y; Suzuki T; Yoshino H
J Control Release; 2002 Apr; 80(1-3):295-307. PubMed ID: 11943406
[TBL] [Abstract][Full Text] [Related]
14. Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy.
Lv X; Zhao M; Wang Y; Hu X; Wu J; Jiang X; Li S; Cui C; Peng S
Drug Des Devel Ther; 2016; 10():3933-3946. PubMed ID: 27942204
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of cisplatin incorporated into polylactic acid microcapsules.
Araki H; Tani T; Kodama M
Artif Organs; 1999 Feb; 23(2):161-8. PubMed ID: 10027886
[TBL] [Abstract][Full Text] [Related]
16. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.
Morinaga Y; Suga Y; Ehara S; Harada K; Nihei Y; Suzuki M
Cancer Sci; 2003 Feb; 94(2):200-4. PubMed ID: 12708497
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy.
Jones SB; Tiffany LJ; Garmestani K; Gansow OA; Kozak RW
Nucl Med Biol; 1996 Feb; 23(2):105-13. PubMed ID: 8868281
[TBL] [Abstract][Full Text] [Related]
18. A poly(γ, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery.
Xiong Y; Jiang W; Shen Y; Li H; Sun C; Ouahab A; Tu J
Biomaterials; 2012 Oct; 33(29):7182-93. PubMed ID: 22795851
[TBL] [Abstract][Full Text] [Related]
19. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin.
Giacomelli S; Gallo D; Apollonio P; Ferlini C; Distefano M; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Life Sci; 2002 Feb; 70(12):1447-59. PubMed ID: 11883719
[TBL] [Abstract][Full Text] [Related]
20. Attenuating the toxicity of cisplatin by using selenosulfate with reduced risk of selenium toxicity as compared with selenite.
Zhang J; Peng D; Lu H; Liu Q
Toxicol Appl Pharmacol; 2008 Feb; 226(3):251-9. PubMed ID: 17950769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
